• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

    135.15 +0.88 (+0.66%)
    Streaming Delayed Price Updated: 9:42 AM EDT, Jul 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Protagonist Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    News headline image
    Protagonist Therapeutics Reports Granting of Inducement Awards
    From Protagonist Therapeutics
    Via ACCESS Newswire
    News headline image
    Protagonist Therapeutics Reports Granting of Inducement Awards
    From Protagonist Therapeutics
    Via ACCESS Newswire
    News headline image
    Protagonist Therapeutics Reports Granting of Inducement Awards
    From Protagonist Therapeutics
    Via ACCESS Newswire
    Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum ↗
    Via Chartmill
    News headline image
    Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
    Via ACCESS Newswire
    News headline image
    Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
    This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
    This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
    Via The Motley Fool
    News headline image
    Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
    Via ACCESS Newswire
    News headline image
    Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
    This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
    Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases. 
    Via The Motley Fool
    News headline image
    Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
    Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases. 
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    News headline image
    Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
    Via ACCESS Newswire
    News headline image
    Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
    Via ACCESS Newswire
    News headline image
    Protagonist Therapeutics Reports Granting of Inducement Awards
    Via ACCESS Newswire
    News headline image
    Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
    Via ACCESS Newswire
    News headline image
    FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
    In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of... 
    Via MarketMinute
    News headline image
    This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
    This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
    Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
    RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
    Via ACCESS Newswire
    News headline image
    Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    News headline image
    CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    Via ACCESS Newswire
    News headline image
    Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    Via ACCESS Newswire
    News headline image
    Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
    This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
    Via ACCESS Newswire
    News headline image
    Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗
    This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗
    The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    "Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
    As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
    Via ACCESS Newswire
    News headline image
    Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.